Anemia of hematologic malignancies: What are the treatment options?

Seminars in Oncology

Volumn 29, Issue 3 SUPPL. 8, 2002, Pages 45-54

  Ludwig, Heinz ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION REACTION; CHRONIC LYMPHATIC LEUKEMIA; CONFERENCE PAPER; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; EXHAUSTION; FATIGUE; HEMATOLOGIC DISEASE; HEMOGLOBIN DETERMINATION; HUMAN; INCIDENCE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SYMPTOMATOLOGY;

EID: 0036291683     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0093-7754(02)70174-7     Document Type: Conference Paper

References (50)

1. Clinical staging of chronic lymphocytic leukemia
2. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis
3. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival
4. Transfusion risks and limitations
5. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial
6. Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors
7. The impact of epoetin alfa on quality of life during cancer chemotherapy: A fresh look at an old problem
8. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study
9. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing
10. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production
11. Progress in understanding the pathogenesis of the anemia of chronic disease
12. Erythropoiesis and erythropoietin in multiple myeloma
13. Multiple myeloma: Review of 869 cases
14. A new staging system for multiple myeloma based on the number of S-phase plasma cells
15. Bone marrow histologic pattern - The best single prognostic parameter in chronic lymphocytic leukemia: A multivariate survival analysis of 329 cases
16. B-chronic lymphocytic leukemia, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma, including Waldenstrom's macroglobulinemia: A clinical, morphologic, and biologic spectrum of similar disorders
17. Anemia associated with nonplatinum chemotherapy (CT) for Hodgkin's Lymphoma (HL) or non-Hodgkin's Lymphoma (NHL)
18. Reports of 355 transfusion-associated deaths: 1976 Through 1985
19. Special report: Transfusion risks
20. Effect of perioperative blood transfusions on recurrence of colorectal cancer: Meta-analysis stratified on risk factors
21. Recombinant human erythropoietin (rHuEPO) therapy in patients with cancer-related anaemia: What have we learned?
22. Erythropoietin treatment of anemia associated with multiple myeloma
23. Recombinant human erythropoietin (rHuEPO) is effective in correcting the anemia of multiple myeloma (MM)
24. Recombinant human erythropoietin in the treatment of multiple mycloma-associated anemia
25. Clinical results of recombinant erythropoietin in transfusion-dependent patients with refractory multiple myeloma: Role of cytokines and monitoring of erythropoiesis
26. Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial
27. Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma
28. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma
29. Recombinant human erythropoietin in the anemia associated with multiple myeloma and non-Hodgkin's lymphoma: Dose finding and identification of predictors of response
30. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - A randomized multicenter study
31. Clinical and health status assessments in anemic chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa (EPO)
32. Effective treatment of disease-related anaemia in B-chronic lymphocytic leukaemia patients with recombinant human erythropoietin
33. Correction of disease related anaemia of B-chronic lymphoproliferative disorders by recombinant human erythropoietin: Maintenance is necessary to sustain response
34. The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietin
35. Measurement of serum cytokine levels in patients with myelodys-plastic syndromes
36. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders: Results of a phase I/II clinical trial
37. Improvement of anemia by recombinant erythropoietin in patients with myelodysplastic syndromes and aplastic anemia
38. High-dose recombinant human erythropoietin administered intravenously for the treatment of anaemia in myelodysplastic syndromes
39. Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes
40. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes: A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes
41. Efficacy of erythropoietin in the myelodysplastic syndromes: A meta-analysis of 205 patients from 17 studies
42. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin
43. Erythroid response to treatment with G-CSF plus erythropoietin for the anemia of patients with myelodysplastic syndromes: Proposal for a predictive model
44. Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome
45. Erythropoietin (RhuEPO) plus G-CSF in the treatment of anemia in myelodysplastic syndromes (MDS): Results of a randomized trial with impact on quality of life and costs
46. Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens
47. Prediction of response to erythropoietin treatment in chronic anemia of cancer
48. Clinical application of recombinant erythropoietin in anemic cancer patients
49. Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy